Regulatory B cells in cancer

被引:109
作者
Michaud, Daniel [1 ,2 ]
Steward, Colleen R. [1 ,3 ]
Mirlekar, Bhalchandra [1 ,4 ]
Pylayeva-Gupta, Yuliya [1 ]
机构
[1] Univ N Carolina, Lineberger Comprehens Canc Ctr, Sch Med, Chapel Hill, NC 27515 USA
[2] Univ N Carolina, Dept Cell Biol & Physiol, Sch Med, Chapel Hill, NC 27515 USA
[3] Univ N Carolina, Dept Microbiol & Immunol, Sch Med, Chapel Hill, NC 27515 USA
[4] Univ N Carolina, Dept Genet, Sch Med, Chapel Hill, NC 27515 USA
关键词
cancer; IL‐ 35; regulatory B cells; tumor immunology; TERTIARY LYMPHOID STRUCTURES; TOLEROGENIC DENDRITIC CELLS; INFILTRATING PLASMA-CELLS; CD4(+) T-CELLS; SUPPRESSOR-CELLS; IMMUNE CELLS; DELAYED-HYPERSENSITIVITY; PROGNOSTIC RELEVANCE; INDUCED ARTHRITIS; TUMOR-GROWTH;
D O I
10.1111/imr.12939
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Tumorigenesis proceeds through discrete steps where acquisition of genetic lesions and changes in the surrounding microenvironment combine to drive unrestricted neoplastic proliferation and metastasis. The ability of tumor-infiltrating immune cells to promote tumor growth via the provision of signals that enable tumor cell survival and proliferation as well as contribute to immune suppression is an active area of research. Recent efforts have provided us with mechanistic insights into how B cells can positively and negatively regulate immune responses. Negative regulation of immune responses in cancer can be mediated by regulatory B cells and is often a result of increased production of cytokines that can directly and indirectly affect anti-tumor immune function and cancer cell growth. Signals that lead to the expansion of regulatory B cells and the spectrum of their functional roles are not well understood and are the subject of active research by many groups. Here, we elaborate broadly on the history of regulatory B cells in cancer and summarize recent studies that have established genetic models for the study of regulatory B cell function and their potential for therapeutic intervention in the setting of solid cancers.
引用
收藏
页码:74 / 92
页数:19
相关论文
共 181 条
  • [1] B Cells Regulate Macrophage Phenotype and Response to Chemotherapy in Squamous Carcinomas
    Affara, Nesrine I.
    Ruffell, Brian
    Medler, Terry R.
    Gunderson, Andrew J.
    Johansson, Magnus
    Bornstein, Sophia
    Bergsland, Emily
    Steinhoff, Martin
    Li, Yijin
    Gong, Qian
    Ma, Yan
    Wiesen, Jane F.
    Wong, Melissa H.
    Kulesz-Martin, Molly
    Irving, Bryan
    Coussens, Lisa M.
    [J]. CANCER CELL, 2014, 25 (06) : 809 - 821
  • [2] Depletion of normal B cells with rituximab as an adjunct to IL-2 therapy for renal cell carcinoma and melanoma
    Aklilu, M
    Stadler, WM
    Markiewicz, M
    Vogelzang, NJ
    Mahowald, M
    Johnson, M
    Gajewski, TF
    [J]. ANNALS OF ONCOLOGY, 2004, 15 (07) : 1109 - 1114
  • [3] Prognostic effect of epithelial and stromal lymphocyte infiltration in non-small cell lung cancer
    Al-Shibli, Khalid I.
    Donnem, Tom
    Al-Saad, Samer
    Persson, Magnus
    Bremnes, Roy M.
    Busund, Lill-Tove
    [J]. CLINICAL CANCER RESEARCH, 2008, 14 (16) : 5220 - 5227
  • [4] B-cell-derived lymphotoxin promotes castration-resistant prostate cancer
    Ammirante, Massimo
    Luo, Jun-Li
    Grivennikov, Sergei
    Nedospasov, Sergei
    Karin, Michael
    [J]. NATURE, 2010, 464 (7286) : 302 - U187
  • [5] FcRγ Activation Regulates Inflammation-Associated Squamous Carcinogenesis
    Andreu, Pauline
    Johansson, Magnus
    Affara, Nesrine I.
    Pucci, Ferdinando
    Tan, Tingting
    Junankar, Simon
    Korets, Lidiya
    Lam, Julia
    Tawfik, David
    DeNardo, David G.
    Naldini, Luigi
    de Visser, Karin E.
    De Palma, Michele
    Coussens, Lisa M.
    [J]. CANCER CELL, 2010, 17 (02) : 121 - 134
  • [6] B regulatory cells in cancer
    Balkwill, Frances
    Montfort, Anne
    Capasso, Melanie
    [J]. TRENDS IN IMMUNOLOGY, 2013, 34 (04) : 169 - 173
  • [7] B lymphocyte pathology in human colorectal cancer. Experimental and clinical therapeutic effects of partial B cell depletion
    Barbera-Guillem, E
    Nelson, MB
    Barr, B
    Nyhus, JK
    May, KF
    Feng, L
    Sampsel, JW
    [J]. CANCER IMMUNOLOGY IMMUNOTHERAPY, 2000, 48 (10) : 541 - 549
  • [8] Understanding the tumor immune microenvironment (TIME) for effective therapy
    Binnewies, Mikhail
    Roberts, Edward W.
    Kersten, Kelly
    Chan, Vincent
    Fearon, Douglas F.
    Merad, Miriam
    Coussens, Lisa M.
    Gabrilovich, Dmitry I.
    Ostrand-Rosenberg, Suzanne
    Hedrick, Catherine C.
    Vonderheide, Robert H.
    Pittet, Mikael J.
    Jain, Rakesh K.
    Zou, Weiping
    Howcroft, T. Kevin
    Woodhouse, Elisa C.
    Weinberg, Robert A.
    Krummel, Matthew F.
    [J]. NATURE MEDICINE, 2018, 24 (05) : 541 - 550
  • [9] Selective Targeting of B Cells with Agonistic Anti-CD40 Is an Efficacious Strategy for the Generation of Induced Regulatory T2-Like B Cells and for the Suppression of Lupus in MRL/lpr Mice
    Blair, Paul A.
    Chavez-Rueda, Karina A.
    Evans, Jamie G.
    Shlomchik, Mark J.
    Eddaoudi, Ayad
    Isenberg, David A.
    Ehrenstein, Michael R.
    Mauri, Claudia
    [J]. JOURNAL OF IMMUNOLOGY, 2009, 182 (06) : 3492 - 3502
  • [10] Anti-CD20 Antibody Promotes Cancer Escape via Enrichment of Tumor-Evoked Regulatory B Cells Expressing Low Levels of CD20 and CD137L
    Bodogai, Monica
    Chang, Catalina Lee
    Wejksza, Katarzyna
    Lai, Jinping
    Merino, Maria
    Wersto, Robert P.
    Gress, Ronald E.
    Chan, Andrew C.
    Hesdorffer, Charles
    Biragyn, Arya
    [J]. CANCER RESEARCH, 2013, 73 (07) : 2127 - 2138